Amesite Signs NurseMagic Enterprise Agreement Serving 2,000 Patients

Amesite Inc. (AMST) signed a NurseMagic enterprise agreement with a healthcare provider serving 2,000 patients, expanding its customer base. The deal is expected to boost revenue and user base, though no contract value was disclosed. NurseMagic automates documentation and EMR workflows within existing systems, and Amesite claims it can deploy customer-specific capabilities quickly.

Original reporting
Published Nov 17, 2026, 11:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 11:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Amesite Signs NurseMagic Enterprise Agreement Serving 2,000 Patients — source image
Decision brief

The 30-second read

$AMSTBullishLow
01

Why it matters

The agreement expands Amesite’s enterprise footprint and patient census exposure, which can improve revenue/user metrics, but the absence of disclosed financial terms limits estimate revisions.

02

Market read

Traders may view this as incremental growth news for AMST, though the undisclosed contract value reduces near-term trading urgency.

03

What to watch

Customer concentration and renewal terms are unknown; deployment speed “in days” may reflect onboarding rather than full utilization, affecting realized revenue timing.

Relevance 6/10Novelty 6/10Timing: immediate post-8-K contract announcement (Nov. 17, 2026)

Background

The piece summarizes an SEC 8-K filing announcing a new enterprise agreement for NurseMagic automation within existing EMR workflows.

Company-level read

Ticker impact

$AMSTBullishMedium confidence
Context

Amesite signed a new NurseMagic enterprise agreement with a healthcare organization serving about 2,000 patients, expanding its enterprise customer base.

Expected impact

Likely modest positive bias as investors price incremental ARR/user growth, tempered by the undisclosed contract size.

Evidence & confidence

The article is a fresh 8-K-backed contract announcement, but it provides no contract value or financial terms, reducing precision for near-term estimates.

Market effects

Supports the broader narrative of EMR workflow automation vendors winning enterprise healthcare deployments, especially in rural Medicare/Medicaid settings.

No specific geography disclosed beyond rural Medicare/Medicaid populations; limited regional read-through.

Primarily US healthcare IT adoption signal; minimal direct global market linkage.

Counterpoint

Without contract value or implementation milestones, the deal may be small relative to revenue, making the market reaction muted.

Key entities

  • Amesite Inc.

    US-listed company (AMST) signing the NurseMagic enterprise agreement.

  • NurseMagic

    Automation platform for documentation and EMR workflows within existing systems.

Related articles

$TLNMed

Talen Signs 750 MW Long-Term Capacity Agreement

Talen Energy (TLN) signed a 7-year, 750 MW capacity agreement with an investment-grade counterparty in PJM, expected to generate $100M annually. The deal covers 2029-2036 and increases Talen's contracted gross margin to 40% through 2036, improving cash flow visibility and reducing earnings risk. Additional agreements contract 1.29 GW of capacity for 2029-2032.

$NNVCMed

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox

NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.